RIGL Rigel Pharmaceuticals
- 1.070
- +0.020+1.90%
Rigel Pharmaceuticals News
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on...
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. The recent drop has obliterate
Rigel Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients With Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 ...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year
Rigel Pharmaceuticals Is Maintained at Buy by Citigroup
Rigel Pharmaceuticals Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals with a Buy and raises the price target from $3 to $4.
New Corporate Activity and Growth Risk for Rigel Pharmaceuticals – What's the Latest?
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Rigel Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Maintains $1.25 Price Target
B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals with a Neutral and maintains $1.25 price target.
Earnings Call Summary | Rigel Pharmaceuticals(RIGL.US) Q4 2023 Earnings Conference
The following is a summary of the Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript:Financial Performance:Rigel recorded 2023 sales of $104 million for TAVALISSE and REZLIDHIA, a gro
Rigel Pharmaceuticals: Q4 Earnings Insights
Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsRigel Pharmaceuticals beat
Rigel Pharmaceuticals GAAP EPS of $0.00 Beats by $0.02, Revenue of $35.8M Beats by $2.39M
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, Vs. Street Est of $33.4M
04:02 PM EST, 03/05/2024 (MT Newswires) -- Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M
Press Release: Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., March 5, 2024 -- Fourth quarter 2023 Total Revenue of $35.
Rigel Pharmaceuticals 4Q Rev $35.8M >RIGL
Rigel Pharmaceuticals 4Q Rev $35.8M >RIGL
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings
Analysis
Price Target
No Data
